Orion Biotech Opportunities (ORIAW) 10-Q2022 Q1 Quarterly report

Filed: 10 May 22, 6:59pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	Coll. sophomore Bad

New words: ability, abovementioned, absolute, accessed, achieving, adverse, adversely, aid, announced, annual, assistance, assurance, Atlantic, chain, commodity, complex, Compliance, conceived, conflict, consult, consulted, consulting, context, costly, country, created, debt, deficiency, deployed, detected, disruption, duration, eastern, economic, economy, EDGAR, effort, enacted, enhancing, escalation, Europe, European, expanded, expend, expended, exposed, expressly, extensive, fact, failure, fairly, fraud, geopolitical, global, heightening, highly, identification, immaterial, impair, important, improve, improvement, increase, increased, increasing, increasingly, instability, instituted, institution, Interbank, invasion, involve, involving, July, Kingdom, lack, lead, led, legislation, length, likelihood, literature, local, matter, met, military, misstatement, monitoring, NATO, North, omitted, partly, predict, prevent, prevented, properly, protectionist, quarter, regional, regularly, remediation, resource, retaliatory, Russia, Russian, scale, shell, Society, succeed, supply, SWIFT, technical, Telecommunication, Treaty, Ukraine, ultimately, Union, unpredictable, unusual, update, view, website, world, Worldwide

Removed: ASU, August, chief, disclose, discrepancy, financing, investing, noncash, reconcile, removing, scope, selected, settlement, Subtopic, Supplemental

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ORIAW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Orion Biotech Opportunities Corp. (the “Company”) on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Huang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2022	/s/ James Huang
	Name:	James Huang
	Title:	Chief Executive Officer
		(Principal Executive Officer)